PRCT:NSD-Procept Biorobotics Corp (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 65.19

Change

-0.33 (-0.50)%

Market Cap

USD 3.18B

Volume

0.29M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-10 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

-1.88 (-2.70%)

USD 44.59B
ALGN Align Technology Inc

+0.72 (+0.31%)

USD 17.40B
PODD Insulet Corporation

+0.56 (+0.29%)

USD 13.78B
BRKR Bruker Corporation

+0.57 (+0.84%)

USD 9.37B
MASI Masimo Corporation

+0.54 (+0.51%)

USD 5.83B
TMDX TransMedics Group Inc

+3.83 (+2.77%)

USD 5.12B
AXNX Axonics Modulation Technologie..

+0.04 (+0.06%)

USD 3.50B
NARI Inari Medical Inc

-5.55 (-10.65%)

USD 3.22B
IRTC iRhythm Technologies Inc

-2.85 (-3.20%)

USD 3.08B
LIVN LivaNova PLC

-1.90 (-3.70%)

USD 2.87B

ETFs Containing PRCT

W311:XETRA HAN-GINS Indxx Healthcare.. 1.54 % 0.00 %

+0.03 (+0.00%)

USD 0.02B
W311:F HAN-GINS Indxx Healthcare.. 1.54 % 0.00 %

N/A

USD 0.02B
WELL:PA HAN-GINS Indxx Healthcare.. 1.54 % 0.00 %

+0.03 (+0.00%)

N/A
WELL:SW HAN-GINS Indxx Healthcare.. 1.54 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 55.55% 91% A- 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 55.55% 91% A- 92% A
Trailing 12 Months  
Capital Gain 71.24% 98% N/A 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 71.24% 98% N/A 94% A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 14.22% 66% D+ 73% C
Dividend Return 14.22% 66% D+ 72% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 36.01% 81% B- 51% F
Risk Adjusted Return 39.50% 88% B+ 71% C-
Market Capitalization 3.18B 93% A 85% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector